|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0002965,
umls-concept:C0005821,
umls-concept:C0016011,
umls-concept:C0027051,
umls-concept:C0030705,
umls-concept:C0037088,
umls-concept:C0039082,
umls-concept:C0332161,
umls-concept:C0332206,
umls-concept:C0443343,
umls-concept:C0449450,
umls-concept:C0475224,
umls-concept:C0597357,
umls-concept:C1273870,
umls-concept:C1274040,
umls-concept:C1514761,
umls-concept:C1549479,
umls-concept:C2603343
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
2000-11-17
|
|
pubmed:abstractText |
Diabetic patients who present with unstable angina or non-ST-elevation myocardial infarction suffer a substantially greater incidence of subsequent infarction or death compared with nondiabetic patients. The present study was undertaken to examine whether diabetic patients in the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study appeared to benefit from platelet glycoprotein IIb/IIIa receptor-mediated inhibition of platelet aggregation by tirofiban.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
14
|
|
pubmed:volume |
102
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2466-72
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11076818-Aged,
pubmed-meshheading:11076818-Angina, Unstable,
pubmed-meshheading:11076818-Anticoagulants,
pubmed-meshheading:11076818-Aspirin,
pubmed-meshheading:11076818-Diabetes Complications,
pubmed-meshheading:11076818-Disease Progression,
pubmed-meshheading:11076818-Double-Blind Method,
pubmed-meshheading:11076818-Drug Administration Schedule,
pubmed-meshheading:11076818-Drug Therapy, Combination,
pubmed-meshheading:11076818-Female,
pubmed-meshheading:11076818-Heparin,
pubmed-meshheading:11076818-Humans,
pubmed-meshheading:11076818-Infusions, Intravenous,
pubmed-meshheading:11076818-Likelihood Functions,
pubmed-meshheading:11076818-Male,
pubmed-meshheading:11076818-Middle Aged,
pubmed-meshheading:11076818-Myocardial Infarction,
pubmed-meshheading:11076818-Platelet Aggregation Inhibitors,
pubmed-meshheading:11076818-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:11076818-Proportional Hazards Models,
pubmed-meshheading:11076818-Survival Analysis,
pubmed-meshheading:11076818-Treatment Outcome,
pubmed-meshheading:11076818-Tyrosine
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study.
|
|
pubmed:affiliation |
Montreal Heart Institute, Montreal, Canada. theroux@ICM.UMontreal.ca
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
